This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Nathan K. Salky, MD; Nicholas R. Di Luzio, PhD; David B. P' Pool, MD; Arthur J. Sutherland, MD

JAMA. 1964;187(10):744-748.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The CONCEPT of the reticuloendothelial system (RES) as groups of fixed macrophages in various organs which are related functionally and morphologically was developed by Aschoff in 1924.¹ Since that time, experimental studies have amply documented the involvement of the RES in areas of lipid metabolism, tumor growth, antibody production, and general host resistance,² but lack of a practical method of measuring RE function in man has hindered an accurate estimation of its clinical significance.

In experimental studies, colloidal substances which are known to be phagocytized by RE cells and whose rate of disappearance from the circulation can be measured, such as colloidal gold or carbon, are employed to evaluate RE function. Since these colloids are not metabolized, they cannot be safely administered to human subjects in doses large enough to determine RE phagocytic activity or capacity. Recently, I¹³¹-labeled aggregated albumin has been developed for the clinical . . . [Full Text PDF of this Article]

Author Affiliations
Memphis

From the departments of physiology and medicine, University of Tennessee Medical Units.

Footnotes
Read before the session on immune processes and microbiology of the Third Multiple Discipline Research Forum during the 112th Annual Meeting of the American Medical Association, Atlantic City, NJ, June 20, 1963.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?